J Korean Med Sci.  2021 Jan;36(4):e28. 10.3346/jkms.2021.36.e28.

Perspectives of Ketamine Use in COVID-19 Patients

• Weinbroum AA

• KMID: 2511633
• DOI: http://doi.org/10.3346/jkms.2021.36.e28

Abstract

Hospitalized coronavirus disease 2019 (COVID-19)-infected patients suffer from both physical impairments and mental stress. Respiratory insufficiency and cardiovascular disturbances require most of the intensive care interventions, but they are also accompanied by depressive conditions, sadness and fear of dying. Sedatives are mostly respiratory and cardiovascular depressants and do not provide resistance to the pro-inflammatory burst induced by the virus. Ketamine is a unique and safe drug that enables well-controlled sedation and anesthesia, attenuates depression and mitigates suicidal thoughts, without depressing respiratory or cardiovascular mechanics. This brief communication highlights the benefits potentially provided by ketamine to patients hospitalized for COVID-19 infection.

Keyword

Ketamine; COVID-19; Sedation; Depression

Reference

1. Strang P, Bergström J, Martinsson L, Lundström S. Dying From COVID-19: loneliness, end-of-life discussions, and support for patients and their families in nursing homes and hospitals. A national register study. J Pain Symptom Manage. 2020; 60(4):e2–13. PMID: 32721500.

2. Weinbroum AA. A single small dose of postoperative ketamine provides rapid and sustained improvement in morphine analgesia in the presence of morphine-resistant pain. Anesth Analg. 2003; 96(3):789–795. PMID: 12598264.

3. Weinbroum AA. Non-opioid IV adjuvants in the perioperative period: pharmacological and clinical aspects of ketamine and gabapentinoids. Pharmacol Res. 2012; 65(4):411–429. PMID: 22311381.

4. Nesher N, Serovian I, Marouani N, Chazan S, Weinbroum AA. Ketamine spares morphine consumption after transthoracic lung and heart surgery without adverse hemodynamic effects. Pharmacol Res. 2008; 58(1):38–44. PMID: 18602474.

5. Dale O, Somogyi AA, Li Y, Sullivan T, Shavit Y. Does intraoperative ketamine attenuate inflammatory reactivity following surgery? A systematic review and meta-analysis. Anesth Analg. 2012; 115(4):934–943. PMID: 22826531.

6. Welters ID, Feurer MK, Preiss V, Müller M, Scholz S, Kwapisz M, et al. Continuous S-(+)-ketamine administration during elective coronary artery bypass graft surgery attenuates pro-inflammatory cytokine response during and after cardiopulmonary bypass. Br J Anaesth. 2011; 106(2):172–179. PMID: 21138901.

7. Peng X, Mosser DM, Adler MW, Rogers TJ, Meissler JJ Jr, Eisenstein TK. Morphine enhances interleukin-12 and the production of other pro-inflammatory cytokines in mouse peritoneal macrophages. J Leukoc Biol. 2000; 68(5):723–728. PMID: 11073113.

8. Can A, Zanos P, Moaddel R, Kang HJ, Dossou KS, Wainer IW, et al. effects of ketamine and ketamine metabolites on evoked striatal dopamine release, dopamine receptors, and monoamine transporters. J Pharmacol Exp Ther. 2016; 359(1):159–170. PMID: 27469513.

9. Su X, Zhu W, Tian Y, Tan L, Wu H, Wu L. Regulatory effects of propofol on high-dose remifentanil-induced hyperalgesia. Physiol Res. 2020; 69(1):157–164. PMID: 31852207.

10. Park HY, Jung J, Park HY, Lee SH, Kim ES, Kim HB, et al. Psychological consequences of survivors of COVID-19 pneumonia 1 month after discharge. J Korean Med Sci. 2020; 35(47):e409. PMID: 33289371.

11. Sher L. COVID-19, anxiety, sleep disturbances and suicide. Sleep Med. 2020; 70:124. PMID: 32408252.

12. Corriger A, Pickering G. Ketamine and depression: a narrative review. Drug Des Devel Ther. 2019; 13:3051–3067.